Sarina Losch
Overview
Explore the profile of Sarina Losch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fellenberg J, Losch S, Arango-Ospina M, Hildenbrand N, Tripel E, Deng L, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39409160
Despite advances in treatment modalities, bone tumour therapies still face significant challenges. Severe side effects of conventional approaches, such as chemo- and radiation therapy, result in poor survival rates and...
2.
Fellenberg J, Losch S, Tripel E, Lehner B, Melnik S
Cells
. 2024 Jan;
13(1).
PMID: 38201265
Although urgently needed, no significant improvements in osteosarcoma (OS) therapy have been achieved within the last decades. Here, we present a new therapeutic approach based on drug combinations consisting of...
3.
Fellenberg J, Losch S, Marinescu M, Frey B, Lehner B, Arango-Ospina M, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980753
Tumor recurrence is a major problem during the treatment of giant cell tumors of bone (GCTB). We recently identified tumor cell-specific cytotoxic effects of bioactive glasses (BGs) toward neoplastic stromal...
4.
Fellenberg J, Losch S, Lehner B, Arango-Ospina M, Boccaccini A, Westhauser F
Bioact Mater
. 2022 Apr;
15:456-468.
PMID: 35386334
Giant cell tumors of bone (GCTB) are associated with massive bone destructions and high recurrence rates. In a previous study, we observed cytotoxic effects of three different compositions of bioactive...
5.
Westhauser F, Arango-Ospina M, Losch S, Wilkesmann S, Lehner B, Ali M, et al.
Biomaterials
. 2021 Jun;
275:120977.
PMID: 34175562
Semi-malignant giant cell tumors of bone (GCTB) are associated with large osteolytic defects and significant bone destructions. Surgical resection remains the standard therapy that is, however, associated with very high...